Skip to Content
ETFs

ETFMG Treatments Testing and Advancements ETF

GERM
$--
Today’s Change
-- (--)

Snapshot
*

Inception Date
Jun 17 2020
Expense Ratio
0.68%
Type
US Equities
Fund Owner
ETF Managers Group
Volume (1m avg. daily)
$23,479
AUM
$13,424,850
Associated Index
Prime Treatments Testing and Advancements Index
Inverse/Leveraged
No
Passive/Active
Passive
Fractionable on Composer
No
Prospectus
View

Top 10 Holdings

LH
Laboratory Corp. Of America Holdings
6.43%
DGX
Quest Diagnostics, Inc.
6.13%
MRNA
Moderna Inc
5.77%
ALNY
Alnylam Pharmaceuticals Inc
5.66%
BNTX
BioNTech SE - ADR
5.64%
PCVX
Vaxcyte Inc
4.39%
ZLAB
Zai Lab Limited - ADR
4.18%
IMCR
Immunocore Holdings plc - ADR
4.02%
DVAX
Dynavax Technologies Corp.
3.86%
BIO
Bio-Rad Laboratories Inc. - Ordinary Shares - Class A
3.84%
Invest with GERM

What is GERM?

The Fund s investment objective seeks to provide investment results that, before fees and expenses, correspond generally to the price and yield performance of the Prime Treatments, Testing and Advancements Index. The Prime Treatments, Testing and Advancements Index is designed to track both event-driven news and long-term trends of companies engaged in developing treatments and vaccines, or diagnostic technology, in the fight against infectious diseases. The Index is designed to include the securities of companies engaged in performing research, development and commercialization of treatments, vaccines or biological testing for infectious diseases. These companies are known collectively as Treatments, Testing and Advancement Companies. The Index has been created to provide investors with a reference measure that enables them to track both event-driven news and long-term trends of companies engaged in developing treatments and vaccines, or diagnostic technology, in the fight against infectious diseases.

ETFs related toGERM

ETFs correlated to GERM include IBB, FBT, LABU

GERM
ETF Managers Trust - ETFMG Treatments Testing and Advancements ETF
IBB
BlackRock Institutional Trust Company N.A. - iShares Biotechnology ETF
FBT
First Trust Exchange-Traded Fund III - First Trust NYSE Arca Biotechnology Index Fund
LABU
Direxion Shares ETF Trust - Direxion Daily S&P Biotech Bull 3X Shares
XBI
SPDR Series Trust - SPDR Biotech ETF
GNOM
Global X Funds - Global X Genomics & Biotechnology ETF
IWC
BlackRock Institutional Trust Company N.A. - iShares Micro-Cap ETF
ARKG
ARK Investment Management LLC - ARK Genomic Revolution ETF
VTWG
Vanguard Group, Inc. - Vanguard Russell 2000 Growth Index ETF
IWO
BlackRock Institutional Trust Company N.A. - iShares Russell 2000 Growth ETF
XHE
SPDR Series Trust - SPDR S&P Health Care Equipment ETF

What is ETF correlation?

Correlation is a measure of the strength of the relationship between two ETFs. It quantifies the degree to which prices of the two ETFs typically move together.

Here, correlation is measured over the past year with the Pearson correlation coefficient (Pearon’s r), which ranges from -1 to 1.

Using ETF correlations in portfolio and strategy construction

ETF correlations can help you create investing strategies and portfolios. Use them to:

  • •Build a diversified portfolio from uncorrelated or inversely correlated ETFs with the aim of minimizing portfolio risk.
  • •Compare correlated or related ETFs to find one with a lower expense ratio or higher trading volume.
  • •Create an investing strategy that hedges an ETF with an uncorrelated or inversely correlated ETF.

FAQ

GERM is a US Equities ETF. The Fund s investment objective seeks to provide investment results that, before fees and expenses, correspond generally to the price and yield performance of the Prime Treatments, Testing and Advancements Index. The Prime Treatments, Testing and Advancements Index is designed to track both event-driven news and long-term trends of companies engaged in developing treatments and vaccines, or diagnostic technology, in the fight against infectious diseases. The Index is designed to include the securities of companies engaged in performing research, development and commercialization of treatments, vaccines or biological testing for infectious diseases. These companies are known collectively as Treatments, Testing and Advancement Companies. The Index has been created to provide investors with a reference measure that enables them to track both event-driven news and long-term trends of companies engaged in developing treatments and vaccines, or diagnostic technology, in the fight against infectious diseases.

GERM tracks the Prime Treatments Testing and Advancements Index.

No, GERM is not actively managed. It is passively managed. In an actively managed fund, the fund manager makes decisions about how funds are invested. A passively managed fund typically tries to track or follow a market index.

Yes, GERM is passively managed. A passively managed fund typically tries to track or follow a market index. In an actively managed fund, the fund manager makes decisions about how funds are invested.

The 1-month return on GERM is -0.0806%. This is the percent change in the value of GERM over the most recent 1-month period. The 3-month return on GERM is -0.1259%. This is the percent change in the value of GERM over the most recent 3-month period.

The standard deviation of GERM for the past year is 0.2613%. Standard deviation is the typical amount that the daily returns vary from the mean of the returns over the time period, standardized to a period of a year.

ETFs similar to GERM include XLI, XLY, and XLV.

ETFs correlated to GERM include IBB, FBT, and LABU.

ETFs that are inversely correlated to GERM include LABD, SRTY, and TZA.

Disclaimers

*

We show information directly obtained from our data provider, Xignite. Data shown here is provided by Xignite, an unaffiliated third party. Composer believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate.

**

We show information based on calculations performed by Composer using data from our provider. Information provided here is based on calculations performed by Composer using data sourced from Xignite, an unaffiliated third party. Composer believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.